- Home
- BMEA vs NUKK Comparison
BMEA vs NUKK Comparison
Compare BMEA & NUKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- NUKK
- Stock Information
- Founded
- BMEA 2017
- NUKK 2013
- Country
- BMEA United States
- NUKK United States
- Employees
- BMEA N/A
- NUKK N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- NUKK Blank Checks
- Sector
- BMEA Health Care
- NUKK Finance
- Exchange
- BMEA Nasdaq
- NUKK Nasdaq
- Market Cap
- BMEA 65.8M
- NUKK 77.4M
- IPO Year
- BMEA 2021
- NUKK N/A
- Fundamental
- Price
- BMEA $1.81
- NUKK $10.60
- Analyst Decision
- BMEA Strong Buy
- NUKK
- Analyst Count
- BMEA 10
- NUKK 0
- Target Price
- BMEA $22.30
- NUKK N/A
- AVG Volume (30 Days)
- BMEA 5.2M
- NUKK 615.6K
- Earning Date
- BMEA 07-30-2025
- NUKK 07-01-2025
- Dividend Yield
- BMEA N/A
- NUKK N/A
- EPS Growth
- BMEA N/A
- NUKK N/A
- EPS
- BMEA N/A
- NUKK N/A
- Revenue
- BMEA N/A
- NUKK N/A
- Revenue This Year
- BMEA N/A
- NUKK N/A
- Revenue Next Year
- BMEA N/A
- NUKK N/A
- P/E Ratio
- BMEA N/A
- NUKK N/A
- Revenue Growth
- BMEA N/A
- NUKK N/A
- 52 Week Low
- BMEA $1.29
- NUKK $1.30
- 52 Week High
- BMEA $13.07
- NUKK $78.32
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- NUKK 37.89
- Support Level
- BMEA $2.24
- NUKK $11.71
- Resistance Level
- BMEA $3.08
- NUKK $11.96
- Average True Range (ATR)
- BMEA 0.40
- NUKK 1.49
- MACD
- BMEA -0.03
- NUKK -0.34
- Stochastic Oscillator
- BMEA 25.07
- NUKK 5.97
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).